Startseite
Märkte
Charts & Ideen
Algo
Nachrichten
Store
Broker
Herunterladen
Wirtschaftskalender
Handelssignale
WebTerminal
Geben Sie
/
ein, um zu suchen: @user, $symbol
Suche
Einloggen
Eröffnen Sie ein Konto
Deutsch
English
Русский
中文
Español
Português
日本語
한국어
Français
Italiano
Türkçe
SMMT
#672
Summit Therapeutics Inc. Common Stock
16.590
0
+7.66%
Sektor:
Basis:
Gewinnwährung:
Tagesspanne
Jahresspanne
Tagesänderung
+7.66%
Monatliche Änderung
+4.60%
6 month change
-16.47%
Jahresänderung
-16.47%
Vorheriger Schlusskurs
15.410
0
Open
16.590
0
Bid
Ask
Low
16.590
0
High
16.590
0
Volumen
263
Märkte
Aktien
Gesundheitswesen
SMMT
Open full chart
Financials
Overview
Finanzbericht
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
82.92 M
98.12 M
697.69 M
701.7 M
737.68 M
775.37 M
—
Valuation ratios
Enterprise value
323.31 M
192.16 M
3.14 B
1.78 B
13.06 B
13.34 B
58.1 B
Price to earnings ratio
-6.18
-2.8
-12.2
-2.67
-57.56
-12.15
-106.61
Price to sales ratio
379.96
137.16
1 371.18
—
—
21.44 K
299.49 K
Price to cash flow ratio
-6.79
-3.42
-23.25
-21.31
-90.23
-40.5
-253.14
Price to book ratio
4.11
2.98
7.63
21.06
32.98
19.85
53.73
Enterprise value to EBITDA ratio
—
—
—
—
—
—
—
Profitability ratios
Return on assets %
0.51
0.78
0.12
3.03
0.51
1.44
3.09
Return on equity %
0.66
1.06
0.62
7.91
0.57
1.64
3.9
Return on invested capital %
831.34
1 235.4
172.33
1 492.71
3 507.86
-10.83 K
—
Gross margin %
100
100
100
—
—
100
400
Operating margin %
6 185.23
4 764.29
10.23 K
—
—
-179.31 K
382.99 K
EBITDA margin %
—
—
—
—
—
—
—
Net margin %
6 127.56
4 897.84
11.17 K
—
—
176.98 K
-368.23 K
Liquidity ratios
Quick ratio
—
—
—
—
—
—
—
Current ratio
4.41
3.8
16.93
9.3
10.15
9.87
29.42
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
0.01
0.02
0
0
0
0
0
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
0.49
0
—
—
Long term debt to total equity ratio
—
—
—
1.29
0
—
—
Per share metrics
Operating cash flow per share
0.69
0.79
0.22
0.12
0.2
0.43
0.43
EBIT per share
—
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
—
Cash per share
0.96
0.78
1.8
0.3
0.57
0.95
2.17
Net current asset value per share
1.26
1.05
3.4
0.31
0.59
0.96
2.22
Tangible book value per share
0.95
0.77
0.65
0.12
0.54
0.88
1.95
Working capital per share
0.97
0.78
3.2
0.27
0.53
0.87
1.9
Book value per share
1.14
0.9
0.66
0.13
0.54
0.88
1.96
Nachrichten
RVMD Reports Wider-Than-Expected Q4 Loss, Issues 2026 Expense View
Summit Therapeutics: H.C. Wainwright senkt Kursziel wegen Unsicherheit bei China-Studie
H.C. Wainwright cuts Summit Therapeutics stock price target on China trial timing uncertainty
SMMT Incurs Wider-Than-Expected Q4 Loss, Pipeline Progress in Focus
Pipeline-Erweiterung: Citizens bestätigt Rating für Summit Therapeutics
Citizens reiterates Summit Therapeutics stock rating on pipeline expansion
Summit Therapeutics Inc. (SMMT) Q4 2025 Earnings Call Transcript
Summit Therapeutics Inc. 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:SMMT) 2026-02-23
Summit Therapeutics: Starke Studiendaten, aber Gewinn pro Aktie verfehlt Ziel um 389 %
Summit Q4 2025 slides: clinical wins offset by 389% EPS miss
Summit Therapeutics verfehlt Gewinnprognose deutlich trotz positiver Studienergebnisse
Earnings call transcript: Summit Therapeutics Q4 2025 reports significant EPS miss